Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications
- 15 February 2005
- journal article
- review article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 573 (1-2) , 180-194
- https://doi.org/10.1016/j.mrfmmm.2004.07.025
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in KoreaRheumatology, 2003
- AZATHIOPRINE-INDUCED FATAL MYELOSUPPRESSION IN A RENAL-TRANSPLANT RECIPIENT WHO CARRIED HETEROZYGOUS TPMT*1/*3CTransplantation, 2003
- Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX‐68Arthritis & Rheumatism, 2003
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Pharmacoeconomics and Health PolicyPharmacoEconomics, 1999
- Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.Journal of Clinical Investigation, 1998
- Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiencyTrends in Pharmacological Sciences, 1995
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995